Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Cannabinoid CB(2) receptor activation by selective agonists has been shown to produce analgesic effects in preclinical models of inflammatory, neuropathic, and bone cancer pain. In this study the effect of a novel CB(2)agonist (MT178) was evaluated in different animal models of pain. First of all, in vitro competition binding experiments performed on rat, mouse, or human CB receptors revealed a high affinity, selectivity, and potency of MT178. The analgesic properties of the novel CB(2) agonist were evaluated in various in vivo experiments, such as writhing and formalin assays, showing a good efficacy comparable with that produced by the nonselective CB agonist WIN 55,212-2. A dose-dependent antiallodynic effect of the novel CB(2) compound in the streptozotocin-induced diabetic neuropathy was found. In a bone cancer pain model and in the acid-induced muscle pain model, MT178 was able to significantly reduce mechanical hyperalgesia in a dose-related manner. Notably, MT178 failed to provoke locomotor disturbance and catalepsy, which were observed following the administration of WIN 55,212-2. CB(2) receptor mechanism of action was investigated in dorsal root ganglia where MT178 mediated a reduction of [(3)H]-d-aspartate release. MT178 was also able to inhibit capsaicin-induced substance P release and NF-κB activation. These results demonstrate that systemic administration of MT178 produced a robust analgesia in different pain models via CB(2) receptors, providing an interesting approach to analgesic therapy in inflammatory and chronic pain without CB(1)-mediated central side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome
Barbara, G., Wang, B., Stanghellini, V., de Giorgio, R., Cremon, C., Di Nardo, G., Trevisani, M., Campi, B., Geppetti, P., Tonini, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.039 · Cited by 783 · cited 1×
“3 lM, Sigma-Aldrich)- and laminin- (5 lM, Sigma-Aldrich) coated 6-well plates and kept in an atmosphere of 5% CO2/95% air at 37 C for 5 days before the experiments [6].”
MethodGuindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305 · cited 1×
“CB1 receptors are expressed at high levels in the central nervous system (CNS) and their activation results in hypothermia, sedation, catalepsy, and altered mental status [20,44].”
BackgroundCB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., & Reggiani, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04684.x · Cited by 290 · cited 1×
“CB2 receptors are well expressed in DRG neurons, as confirmed by previous works that reported CB2 mRNA expression [7,29].”
BackgroundHan, K. H., Lim, S., Ryu, J., Lee, C.-W., Kim, Y., Kang, J.-H., Kang, S.-S., Ahn, Y. K., Park, C.-S., & Kim, J. J. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp240 · Cited by 232
Anand, U., Otto, W. R., Sanchez-Herrera, D., Facer, P., Yiangou, Y., Korchev, Y., Birch, R., Benham, C., Bountra, C., Chessell, I. P., et al. (2008) · Pain · doi:10.1016/j.pain.2008.06.007 · Cited by 166 · cited 1×
“The recent finding demonstrating the presence of CB2 receptor immunoreactivity in dorsal root ganglion (DRG) neurons provides a platform to study functional effects of selective CB2 agonists to better investigate their antinociceptive mechanism of action [2].”
BackgroundHsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139 · cited 1×
“CB2 receptors are well expressed in DRG neurons, as confirmed by previous works that reported CB2 mRNA expression [7,29].”
BackgroundHarrigan, T. J., Abdullaev, I. F., Jourd’heuil, D., & Mongin, A. A. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05553.x · Cited by 103
Cited by
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Novel halogenated derivates of JWH-018: behavioral and binding studies in mice
Vigolo, A., Ossato, A., Trapella, C., Vincenzi, F., Rimondo, C., Seri, C., Varani, K., Serpelloni, G., & Marti, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.008 · Cited by 91
Self-citationGreco, R., Mangione, A. S., Sandrini, G., Nappi, G., & Tassorelli, C. (2014) · The Journal of Headache and Pain · doi:10.1186/1129-2377-15-14 · Cited by 46
Metadata
- Authors
- Vincenzi, F., Targa, M., Corciulo, C., Tabrizi, M. A., Merighi, S., Gessi, S., Saponaro, G., Baraldi, P. G., Borea, P. A., & Varani, K.
- Venue
- Pain
- Published
- 2013-06
- Volume
- 154
- Issue
- 6
- Pages
- 864-873
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2048626163
- Cited by
- 62
- References
- 11
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. https://app.cochat.ai/papers/10.1016/j.pain.2013.02.007
- The paper
- Vincenzi, F., Targa, M., Corciulo, C., Tabrizi, M. A., Merighi, S., Gessi, S., Saponaro, G., Baraldi, P. G., Borea, P. A., & Varani, K. (2013). Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. Pain. https://doi.org/10.1016/j.pain.2013.02.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.